Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation